套细胞淋巴瘤中CD19 CAR T细胞治疗后神经毒性的临床特征
本研究评估了26例接受标准治疗brexucabtagene autoleucel的套细胞淋巴瘤患者,17例(65%)发生免疫效应细胞相关神经毒性综合征(ICANS),中位发生时间为第6天,10例(38%)为重度(≥3级)。所有ICANS患者均先有细胞因子释放综合征(CRS),但ICANS严重程度与CRS分级无相关性。重度ICANS与血细胞减少、凝血病、累积类固醇暴露增加和住院时间延长相关,但不影响治疗结局。
要点
- 26例套细胞淋巴瘤患者中17例(65%)发生ICANS,中位发生时间为第6天。
- 10例(38%)发生重度(≥3级)ICANS,所有ICANS患者均先有CRS。
- 重度ICANS与血细胞减少、凝血病、累积类固醇暴露增加和住院时间延长相关,但不影响治疗结局。
核心结论
- 重度ICANS常与一系列输注后脑MRI改变和异常EEG表现相关。
- 重度ICANS患者住院时间更长,尤其是那些有异常急性MRI或EEG表现的患者,但对总体治疗反应和生存无明显影响。
研究设计与样本
- 本研究评估了截至2022年7月在本机构接受标准治疗brexucabtagene autoleucel的所有患者(N=26)。
- 评估了包括脑磁共振成像(MRI)和脑电图(EEG)在内的实验室和影像学相关指标,以确定ICANS的临床影响。
主要发现
- 17例(65%)患者治疗后发生ICANS,中位发生时间为第6天。
- 10例(38%)患者发生重度(≥3级)ICANS。
- 所有ICANS患者均先有细胞因子释放综合征(CRS),但未观察到ICANS严重程度与CRS分级之间的相关性。
- 总体而言,92%的EEG显示发作间期改变;没有患者因ICANS发生明显癫痫发作。
- 在重度ICANS且有输注后脑MRI的患者中,86%显示治疗前MRI未见到的急性神经影像学发现。
关键数值与推荐
- 重度ICANS还与更高的血细胞减少、凝血病、累积类固醇暴露增加和住院时间延长相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19 chimeric antigen receptor (CAR) T-cell therapy has proven highly effective for treating relapsed/refractory mantle cell lymphoma (MCL). However, immune effector cell-associated neurotoxicity syndrome (ICANS) remains a significant concern. This study aimed to evaluate the clinical, radiological, and laboratory correlatives associated with ICANS development after CD19 CAR T-cell therapy in patients with MCL. All patients (N = 26) who received standard-of-care brexucabtagene autoleucel until July 2022 at our institution were evaluated. Laboratory and radiographic correlatives including brain magnetic resonance imaging (MRI) and electroencephalogram (EEG) were evaluated to determine the clinical impact of ICANS. Seventeen (65%) patients experienced ICANS after treatment, with a median onset on day 6. Ten (38%) patients experienced severe (grade ≥3) ICANS. All patients with ICANS had antecedent cytokine release syndrome (CRS), but no correlation was observed between ICANS severity and CRS grade. Overall, 92% of EEGs revealed interictal changes; no patients experienced frank seizures because of ICANS. In total, 86% of patients with severe ICANS with postinfusion brain MRIs demonstrated acute neuroimaging findings not seen on pretreatment MRI. Severe ICANS was also associated with higher rates of cytopenia, coagulopathy, increased cumulative steroid exposure, and prolonged hospitalization. However, severe ICANS did not affect treatment outcomes of patients with MCL. Severe ICANS is frequently associated with a range of postinfusion brain MRI changes and abnormal EEG findings. Longer hospitalization was observed in patients with severe ICANS, especially those with abnormal acute MRI or EEG findings, but there was no discernible impact on overall treatment response and survival.
引用
- Nie EH, Su YJ, Baird JH, et al. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma. Blood Adv. 2024. PMID: 38295285. doi:10.1182/bloodadvances.2023011896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。